Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04964947 · ClinicalTrials.gov registry record · Phase 3

Tobramycin Injection to Prevent Infection in Open Fractures

A Phase 3 study of Surgical Site Infection and Wound Infection, sponsored by Massachusetts General Hospital.

Active
Registry status
Phase 3
Development phase
600
Enrollment target
3
Study locations

NCT04964947 is a Phase 3 study of Surgical Site Infection and Wound Infection that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 600 participants, above the 544-participant average among 25 other Surgical Site Infection trials with a reported enrollment target (10% higher). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04964947, a Phase 3 study of Surgical Site Infection and Wound Infection, is active but no longer recruiting, sponsored by Massachusetts General Hospital.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
600 participants
Enrollment target
3
Study locations

Study Summary

The goal of open extremity fracture (OEF) treatment is to promote fracture healing and restore function while preventing the development of infection. This is achieved through systematic and timely wound debridement and irrigation, fracture stabilization, tetanus prophylaxis, systemic and local antimicrobial therapy, and judicious timing of wound closure based on cleanliness. Early prophylactic systemic antibiotics lower infection rates in open fractures but have limitations of achieving adequate concentration at the hypoperfused wound area. OEF wounds are frequently poor in vasculature secondary to the soft tissue injury, hence adequate concentration of antibiotic cannot permeate to the tissue at risk. If systemic antibiotic concentrations are increased to achieve minimum inhibitory concentration (MIC) for pathogens at the wound, there is heightened concern for systemic drug toxicity. In sharp contrast, locally administered antibiotics achieve high drug concentration directly within the wound cavity with minimal systemic side effects. Local antibiotic therapy has shown to reduce rates of open fracture wound infection. With the serious implications of postoperative infections in OEF, it is imperative that all measures including further use of prophylactic local antibiotics be considered to prevent fracture-related infection (FRI). The overarching hypothesis for this project is that a novel synergistic combination of local aqueous tobramycin plus perioperative weight-based IV cephalosporin antibiotic prophylaxis will reduce the rate of FRI one year after OEF surgery. This in turn will improve OEF patient outcomes, decreasing morbidity and return to the operating room (OR) without any adverse effect on fracture healing. Regardless of the treatment group, bacterial speciation will be determined for patients that do develop FRI to help guide future treatment. The goal is to improve the clinical outcome and recovery of the population that sustains an OEF by decreasing th

Interventions

  • DRUG Tobramycin Injection

Study Locations (3)

Kentucky

  • University of Kentucky - Lexington

Massachusetts

  • Massachusetts General Hospital - Boston

Tennessee

  • Vanderbilt University Medical Center - Nashville

Trial Details

FieldValue
Enrollment Target 600 participants
Start Date 2022-01-10
Est. Completion 2026-07
Phase Phase 3

Sponsor

Massachusetts General Hospital

2,032 total trials

What the Registry Record Tells You About NCT04964947

The ClinicalTrials.gov registry entry for NCT04964947 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 544-participant average among 25 other Surgical Site Infection trials with a reported enrollment target (10% higher). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Surgical Site Infection appearing as the primary indexed condition, and to 1 intervention - of which Tobramycin Injection is the first listed.

NCT04964947 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Kentucky, Massachusetts, Tennessee.

Frequently Asked Questions

What is clinical trial NCT04964947 about?

NCT04964947 is a clinical study titled "Tobramycin Injection to Prevent Infection in Open Fractures". The goal of open extremity fracture (OEF) treatment is to promote fracture healing and restore function while preventing the development of infection. This is achieved through systematic and timely wound debridement and irrigation, fracture stabilization, tetanus prophylaxis, systemic and local anti...

What is the current status of trial NCT04964947?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 600 participants. The study started on 2022-01-10. Estimated completion is 2026-07.

What conditions does trial NCT04964947 study?

This clinical trial studies the following conditions: Surgical Site Infection, Wound Infection, Fractures, Open.

What interventions are being tested in trial NCT04964947?

The interventions under investigation include: Tobramycin Injection (DRUG).

Who is sponsoring clinical trial NCT04964947?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04964947 being conducted?

This trial has 3 study locations across Kentucky, Massachusetts, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Surgical Site Infection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.